Literature DB >> 19401323

Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome.

A Overbeek1, E A M Kuijper, M L Hendriks, M A Blankenstein, I J G Ketel, J W R Twisk, P G A Hompes, R Homburg, C B Lambalk.   

Abstract

BACKGROUND: Clomiphene citrate (CC) response in anovulatory women is difficult to predict and patient-tailored treatment would benefit patient care and time-management. The objective of this study was to evaluate the role of the follicle-stimulating hormone receptor (FSHR) Ser680Ser-polymorphism as a predictor for CC response.
METHODS: In this retrospective study, 193 patients, diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria and treated with ovulation induction, were included over a 5-year period in a university hospital in the Netherlands. Data on demographics, BMI, menstrual cycle, laboratory screening (including FSHR genotyping), transvaginal ultrasonography of ovaries and ovulation parameters were collected. Main outcome measures were response to CC and FSHR genotype.
RESULTS: The frequency distribution of the 680-polymorphism was 26% (Asn/Asn), 50% (Asn/Ser) and 24% (Ser/Ser). No significant differences in basal characteristics were found. Significantly more patients with Ser/Ser-polymorphism were resistant to CC (28%) compared with Asn/Ser (14%) and Asn/Asn group (15%), with an odds ratio for ovulation of 0.44 (95% CI, 0.21-0.97). Patients with higher FSH levels, higher age and lower BMI were significantly more likely to ovulate in univariate analysis. In a multivariate logistic regression model, corrected for age, BMI, mean ovarian, volume, hyperandrogenism, and amenorrhoea, only FSHR and basal FSH levels were predictive for ovulation.
CONCLUSIONS: Chance of resistance to CC is almost double in women with PCOS harbouring the Ser/Ser genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401323     DOI: 10.1093/humrep/dep114

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  17 in total

Review 1.  Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function.

Authors:  Livio Casarini; Elisa Pignatti; Manuela Simoni
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

2.  Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH.

Authors:  Cengiz Karakaya; Ozlem Guzeloglu-Kayisli; Rebecca J Hobbs; Tsilya Gerasimova; Asli Uyar; Mehmet Erdem; Mesut Oktem; Ahmet Erdem; Seyhan Gumuslu; Deniz Ercan; Denny Sakkas; Pierre Comizzoli; Emre Seli; Maria D Lalioti
Journal:  Mol Hum Reprod       Date:  2014-03-25       Impact factor: 4.025

3.  FSH receptor gene p. Thr307Ala and p. Asn680Ser polymorphisms are associated with the risk of polycystic ovary syndrome.

Authors:  Jin Ju Kim; Young Min Choi; Min A Hong; Soo Jin Chae; Kyuri Hwang; Sang Ho Yoon; Seung Yup Ku; Chang Suk Suh; Seok Hyun Kim
Journal:  J Assist Reprod Genet       Date:  2017-05-25       Impact factor: 3.412

4.  Frequent polymorphisms of FSH receptor do not influence antral follicle responsiveness to follicle-stimulating hormone administration as assessed by the Follicular Output RaTe (FORT).

Authors:  Vanessa Krebs Genro; Ursula Matte; Emily De Conto; João Sabino Cunha-Filho; Renato Fanchin
Journal:  J Assist Reprod Genet       Date:  2012-04-14       Impact factor: 3.412

Review 5.  Pharmacogenetics of follicle-stimulating hormone action.

Authors:  Maris Laan; Marina Grigorova; Ilpo T Huhtaniemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-06       Impact factor: 3.243

Review 6.  Functional genomics of PCOS: from GWAS to molecular mechanisms.

Authors:  Jan M McAllister; Richard S Legro; Bhavi P Modi; Jerome F Strauss
Journal:  Trends Endocrinol Metab       Date:  2015-01-15       Impact factor: 12.015

7.  Reduced FSH and LH action: implications for medically assisted reproduction.

Authors:  E Bosch; C Alviggi; M Lispi; A Conforti; A C Hanyaloglu; D Chuderland; M Simoni; N Raine-Fenning; P Crépieux; S Kol; V Rochira; T D'Hooghe; P Humaidan
Journal:  Hum Reprod       Date:  2021-05-17       Impact factor: 6.918

Review 8.  Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols.

Authors:  Carlo Alviggi; Peter Humaidan; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-02-06       Impact factor: 5.211

9.  N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes.

Authors:  Lekha Saha; Sharonjeet Kaur; Pradip Kumar Saha
Journal:  J Pharmacol Pharmacother       Date:  2013-07

10.  Family-based analysis of eight susceptibility loci in polycystic ovary syndrome.

Authors:  Shigang Zhao; Ye Tian; Xuan Gao; Xiuqing Zhang; Hongbin Liu; Li You; Yongzhi Cao; Shizhen Su; Wai-Yee Chan; Yun Sun; Han Zhao; Zi-Jiang Chen
Journal:  Sci Rep       Date:  2015-07-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.